Cargando…
Original papers: clinical or basic research anti-cyclic citrullinated peptide antibodies - activity markers in rheumatoid arthritis
Background: Immunological abnormalities in rheumatoid arthritis (RA) imply several antibodies, among which anti-cyclic cytrullinated peptide antibodies (anti-CCP) have the highest sensitivity and specificity. Their diagnostic and prognostic value in RA is well known, although their value as markers...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Carol Davila University Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051479/ https://www.ncbi.nlm.nih.gov/pubmed/20108489 |
_version_ | 1782458085362630656 |
---|---|
author | Predeteanu, Denisa Varzaru, Luminita Balanescu, Andra Bojinca, Violeta Opris, Daniela Vlad, Violeta Berghea, Florian Abobului, Mihai Constantinescu, Cosmin Ionescu, Ruxandra |
author_facet | Predeteanu, Denisa Varzaru, Luminita Balanescu, Andra Bojinca, Violeta Opris, Daniela Vlad, Violeta Berghea, Florian Abobului, Mihai Constantinescu, Cosmin Ionescu, Ruxandra |
author_sort | Predeteanu, Denisa |
collection | PubMed |
description | Background: Immunological abnormalities in rheumatoid arthritis (RA) imply several antibodies, among which anti-cyclic cytrullinated peptide antibodies (anti-CCP) have the highest sensitivity and specificity. Their diagnostic and prognostic value in RA is well known, although their value as markers of the disease activity has not been established yet. Objectives: The aim of this study is to evaluate the correlation between anti-CCP antibodies and RA activity which eventually leads to the best treatment of choice. Patients and Methods: 217 consecutive patients hospitalized in the Department of Internal Medicine and Rheumatology, “Sf. Maria” Clinical Hospital between 01.01-31.06 2007 were retrospectively studied. They were divided into two groups: group A-111 patients with RA (ACR criteria fulfilled) and group B-106 patients with other rheumatic diseases. The following parameters taken out of the patients, files were studied: parameters of the clinical activity of disease (C reactive protein, fibrinogen), rheumatoid factor (RF) and anti-CCP antibodies. Disease activity score (DAS) using 4 variables (number of tender joints, number of swollen joints, erythrocyte sedimentation rate and assessement of the disease activity) was also studied. Data were processed with SPSS program using linear functions, Pearson correlation coefficient and Hi2 test of interdependency. Results: The sensitivity of anti-CCP antibodies in patients with RA was 56.75%. The specificity of anti-CCP antibodies in patients with RA was 90.56%. Low seric levels of anti-CCP antibodies were also found in patients without RA, but with other conditions like: osteoarthritis, viral polyarthritis, infectious myositis and Still disease; moderate to high seric levels were found in patients with psoriatic arthritis. Significant correlations were found between anti-CCP antibodies and DAS (r=0.437), between anti-CCP and fibrinogen (r=0,32) between anti-CCP antibodies and C reactive protein (r=0,237) as well as between anti-CCP and RF (r=0, 38). Conclusions: Anti-CCP antibodies are highly specific but moderately sensitive for RA, their highest frequencies and seric levels being found in seropositive RA. Anti-CCP can be used in patients with RA not only as a diagnostic marker but also as a reliable test for assessing the activity of the disease. |
format | Online Article Text |
id | pubmed-5051479 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Carol Davila University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-50514792016-10-21 Original papers: clinical or basic research anti-cyclic citrullinated peptide antibodies - activity markers in rheumatoid arthritis Predeteanu, Denisa Varzaru, Luminita Balanescu, Andra Bojinca, Violeta Opris, Daniela Vlad, Violeta Berghea, Florian Abobului, Mihai Constantinescu, Cosmin Ionescu, Ruxandra J Med Life Original Articles Background: Immunological abnormalities in rheumatoid arthritis (RA) imply several antibodies, among which anti-cyclic cytrullinated peptide antibodies (anti-CCP) have the highest sensitivity and specificity. Their diagnostic and prognostic value in RA is well known, although their value as markers of the disease activity has not been established yet. Objectives: The aim of this study is to evaluate the correlation between anti-CCP antibodies and RA activity which eventually leads to the best treatment of choice. Patients and Methods: 217 consecutive patients hospitalized in the Department of Internal Medicine and Rheumatology, “Sf. Maria” Clinical Hospital between 01.01-31.06 2007 were retrospectively studied. They were divided into two groups: group A-111 patients with RA (ACR criteria fulfilled) and group B-106 patients with other rheumatic diseases. The following parameters taken out of the patients, files were studied: parameters of the clinical activity of disease (C reactive protein, fibrinogen), rheumatoid factor (RF) and anti-CCP antibodies. Disease activity score (DAS) using 4 variables (number of tender joints, number of swollen joints, erythrocyte sedimentation rate and assessement of the disease activity) was also studied. Data were processed with SPSS program using linear functions, Pearson correlation coefficient and Hi2 test of interdependency. Results: The sensitivity of anti-CCP antibodies in patients with RA was 56.75%. The specificity of anti-CCP antibodies in patients with RA was 90.56%. Low seric levels of anti-CCP antibodies were also found in patients without RA, but with other conditions like: osteoarthritis, viral polyarthritis, infectious myositis and Still disease; moderate to high seric levels were found in patients with psoriatic arthritis. Significant correlations were found between anti-CCP antibodies and DAS (r=0.437), between anti-CCP and fibrinogen (r=0,32) between anti-CCP antibodies and C reactive protein (r=0,237) as well as between anti-CCP and RF (r=0, 38). Conclusions: Anti-CCP antibodies are highly specific but moderately sensitive for RA, their highest frequencies and seric levels being found in seropositive RA. Anti-CCP can be used in patients with RA not only as a diagnostic marker but also as a reliable test for assessing the activity of the disease. Carol Davila University Press 2009 /pmc/articles/PMC5051479/ /pubmed/20108489 Text en ©Carol Davila University Press http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Predeteanu, Denisa Varzaru, Luminita Balanescu, Andra Bojinca, Violeta Opris, Daniela Vlad, Violeta Berghea, Florian Abobului, Mihai Constantinescu, Cosmin Ionescu, Ruxandra Original papers: clinical or basic research anti-cyclic citrullinated peptide antibodies - activity markers in rheumatoid arthritis |
title | Original papers: clinical or basic research
anti-cyclic citrullinated peptide antibodies - activity markers in rheumatoid arthritis
|
title_full | Original papers: clinical or basic research
anti-cyclic citrullinated peptide antibodies - activity markers in rheumatoid arthritis
|
title_fullStr | Original papers: clinical or basic research
anti-cyclic citrullinated peptide antibodies - activity markers in rheumatoid arthritis
|
title_full_unstemmed | Original papers: clinical or basic research
anti-cyclic citrullinated peptide antibodies - activity markers in rheumatoid arthritis
|
title_short | Original papers: clinical or basic research
anti-cyclic citrullinated peptide antibodies - activity markers in rheumatoid arthritis
|
title_sort | original papers: clinical or basic research
anti-cyclic citrullinated peptide antibodies - activity markers in rheumatoid arthritis |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051479/ https://www.ncbi.nlm.nih.gov/pubmed/20108489 |
work_keys_str_mv | AT predeteanudenisa originalpapersclinicalorbasicresearchanticycliccitrullinatedpeptideantibodiesactivitymarkersinrheumatoidarthritis AT varzaruluminita originalpapersclinicalorbasicresearchanticycliccitrullinatedpeptideantibodiesactivitymarkersinrheumatoidarthritis AT balanescuandra originalpapersclinicalorbasicresearchanticycliccitrullinatedpeptideantibodiesactivitymarkersinrheumatoidarthritis AT bojincavioleta originalpapersclinicalorbasicresearchanticycliccitrullinatedpeptideantibodiesactivitymarkersinrheumatoidarthritis AT oprisdaniela originalpapersclinicalorbasicresearchanticycliccitrullinatedpeptideantibodiesactivitymarkersinrheumatoidarthritis AT vladvioleta originalpapersclinicalorbasicresearchanticycliccitrullinatedpeptideantibodiesactivitymarkersinrheumatoidarthritis AT bergheaflorian originalpapersclinicalorbasicresearchanticycliccitrullinatedpeptideantibodiesactivitymarkersinrheumatoidarthritis AT abobuluimihai originalpapersclinicalorbasicresearchanticycliccitrullinatedpeptideantibodiesactivitymarkersinrheumatoidarthritis AT constantinescucosmin originalpapersclinicalorbasicresearchanticycliccitrullinatedpeptideantibodiesactivitymarkersinrheumatoidarthritis AT ionescuruxandra originalpapersclinicalorbasicresearchanticycliccitrullinatedpeptideantibodiesactivitymarkersinrheumatoidarthritis |